Therapeutic applications of the gaseous mediators carbon monoxide and hydrogen sulfide.

Abstract:

BACKGROUND:Hydrogen sulfide (H(2)S) and carbon monoxide (CO) are endogenously produced gaseous autacoids that regulate a number of physiological processes, including the inflammatory response, cell death and proliferation, neural transmission and smooth muscle tone. OBJECTIVE/METHODS:The current review aims to provide a comprehensive overview of all recent patent applications that address the potential therapeutic applications of CO and H(2)S. RESULTS/CONCLUSION:Beyond the direct administration of CO and H(2)S, this review highlights the therapeutic applications of a variety of gas-releasing molecules that are being developed to deliver CO and H(2)S to diseased tissues at therapeutic doses. The term autacoid, which, in addition to its pharmacological use to describe a locally-acting hormone, literally translates from Greek as 'self-drug', seems to particularly well describe the current approach to capture the potential therapeutic use of these two gasotransmitters. In summary, we can conclude that there is a markedly growing interest in harnessing the tissue-protective actions of CO and H(2)S.

journal_name

Expert Opin Ther Pat

authors

Bannenberg GL,Vieira HL

doi

10.1517/13543770902858824

subject

Has Abstract

pub_date

2009-05-01 00:00:00

pages

663-82

issue

5

eissn

1354-3776

issn

1744-7674

journal_volume

19

pub_type

杂志文章,评审
  • Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628.

    abstract::A small series of aryl(1-arylamino)ethyl,1,5-naphthyridine derivatives that selectively inhibit PI3Kδ was prepared. The compounds are claimed to be useful in the treatment of cancer, inflammatory and autoimmune diseases. The compounds represent further variations around a structural motif explored in a number of previ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2011.622749

    authors: Norman P

    更新日期:2011-11-01 00:00:00

  • Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.

    abstract:BACKGROUND:The family of G-protein-coupled receptors (GPCRs) serves as the target for almost a third of currently marketed drugs and provides the predominant mechanism through which extracellular factors transmit signals to the cell. GPCRs have been proved to be good therapeutic targets for metabolic disorders. In rece...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770802665717

    authors: Bharate SB,Nemmani KV,Vishwakarma RA

    更新日期:2009-02-01 00:00:00

  • Soluble fms-like tyrosine kinase-1 antibody for diagnosis purposes (WO2010075475).

    abstract:BACKGROUND:The application (WO2010075475) is involved in the diagnosis of angiogenesis-dependent diseases related with the soluble FMS-like tyrosine kinase-1 (sFlt-1) biomarker. OBJECTIVE:It aims to identify, characterize and produce antibodies raised against sFlt-1 for the diagnosis of preeclampsia as well as other c...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2011.577071

    authors: Boyaud F,Inguimbert N

    更新日期:2011-06-01 00:00:00

  • Targeting survivin in cancer: patent review.

    abstract:IMPORTANCE OF THE FIELD:Survivin is a prominent anti-apoptotic molecule expressed widely in the majority of cancers. Overexpression of survivin leads to uncontrolled cancer cell growth and drug resistance. Efficient downregulation of survivin expression and its functions can sensitise the tumour cells to various therap...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2010.533657

    authors: Kanwar JR,Kamalapuram SK,Kanwar RK

    更新日期:2010-12-01 00:00:00

  • Nuclear factor-kappa B inhibitors; a patent review (2006-2010).

    abstract:INTRODUCTION:Nuclear factor (NF)-κB, as transcription factor, is linked to the expression of various genes and plays an essential role in immune and inflammatory responses. Abnormal NF-κB signaling results in human diseases, such as immune disorders, inflammation and various cancers. Therefore, regulation of NF-κB may ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.638285

    authors: Kwak JH,Jung JK,Lee H

    更新日期:2011-12-01 00:00:00

  • Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.

    abstract::In recent years, the involvement of the Hedgehog (Hh) signaling pathway in various human diseases and dysfunctions has been clearly demonstrated. Smoothened (Smo), one of the upstream signal transducers, has been the most druggable target of the Hh pathway. However, the emergence of resistance to Smo inhibitors and th...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2016.1132309

    authors: Manetti F,Petricci E

    更新日期:2016-01-01 00:00:00

  • Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).

    abstract:INTRODUCTION:The non-receptor tyrosine kinase, inducible tyrosine kinase (Itk), plays an important role in thymus(T)-cell signalling and the production of pro-inflammatory cytokines. Itk, and the other Tec family members, Rlk and Tec, are viewed as attractive drug targets for new agents for the treatment of autoimmune ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.936381

    authors: Norman P

    更新日期:2014-09-01 00:00:00

  • Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections.

    abstract:INTRODUCTION:Amino acid depletion in the blood serum is currently being exploited and explored for therapies in tumors or viral infections that are auxotrophic for a certain amino acid or have a metabolic defect and cannot produce it. The success of these treatments is because normal cells remain unaltered since they a...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1254194

    authors: Fernandes HS,Silva Teixeira CS,Fernandes PA,Ramos MJ,Cerqueira NM

    更新日期:2017-03-01 00:00:00

  • Topical composition for treating diabetic cataracts: a patent evaluation (WO2015026380A1).

    abstract::Diabetes mellitus is a major threat to global public health that requires long-term medical attention. In view of the potentially devastating effects of diabetes on ocular health, it highlights the urgent need of therapeutic drugs for the prevention and treatment of the diabetic complications. The patent described in ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2016.1163339

    authors: Hao X,Han Z,Zhu C

    更新日期:2016-06-01 00:00:00

  • Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents.

    abstract::In addition to its central role in haemostasis and wound healing, thrombin activates platelets and smooth muscle cells by proteolytic activation of cell surface protease-activated receptor-1 (PAR-1), which is also known as the thrombin receptor. Thrombin is the most potent activator of human platelets and, as such, a ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.16.4.493

    authors: Chackalamannil S,Xia Y

    更新日期:2006-04-01 00:00:00

  • Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present).

    abstract::Introduction: DNA-dependent protein kinase (DNA-PK) plays a crucial role in the repair of DSBs via non-homologous end joining (NHEJ). Several DNA-PK inhibitors are being investigated for potential anticancer treatment in clinical trials. Area covered: This review aims to give an overview of patents published since 201...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2021.1866540

    authors: Hu S,Hui Z,Lirussi F,Garrido C,Ye XY,Xie T

    更新日期:2020-12-21 00:00:00

  • Rho kinase inhibitors: a patent review (2012 - 2013).

    abstract:INTRODUCTION:The Rho kinase/ROCK is critical in vital signal transduction pathways central to many essential cellular activities. Since ROCK possess multiple substrates, modulation of ROCK activity is useful for treatment of many diseases. AREAS COVERED:Significant progress has been made in the development of ROCK inh...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.863279

    authors: Feng Y,LoGrasso PV

    更新日期:2014-03-01 00:00:00

  • Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.

    abstract:INTRODUCTION:There has been research on anticancer strategies which focus on disrupting a single malignant protein. One of the strategies is the inhibition of one protein, heat shock protein 90 (Hsp90). There are many reasons why Hsp90 protein is targeted by anticancer agents: maintenance of cellular homeostasis in org...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2013.780597

    authors: Kim T,Keum G,Pae AN

    更新日期:2013-08-01 00:00:00

  • Caffeic acid derivatives, analogs and applications: a patent review (2009-2013).

    abstract:INTRODUCTION:Caffeic acid (CA) is broadly distributed in several species of the plant kingdom and is widely consumed in human diet. CA and derivatives have been extensively studied in the past years, which unveiled a broad spectrum of biological activities and potential therapeutic applications. As a result, there has ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.959492

    authors: Silva T,Oliveira C,Borges F

    更新日期:2014-11-01 00:00:00

  • Solid lipid nanoparticles: a review on recent perspectives and patents.

    abstract::Introduction: Solid lipid nanoparticles (SLNs) are solid core lipid nanocarriers, which can hold both hydrophilic and hydrophobic drugs. They can be made up of biocompatible ingredients and therefore are one of the preferred choices for drug delivery. Surface modifications of SLNs may further provide unique features t...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1720649

    authors: Paliwal R,Paliwal SR,Kenwat R,Kurmi BD,Sahu MK

    更新日期:2020-03-01 00:00:00

  • Parthenogenetically activated human oocytes and parthenogenetic embryonic stem cells: US20100233143.

    abstract:BACKGROUND:The application (US20100233143) is in the field of embryonic stems cells (ESCs) and the generation of ESCs from parthenogenetically activated human oocytes. OBJECTIVE:It aims at determining optimal conditions for parthenogenetically activating human oocytes. METHODS:Oocytes isolated from female donors were...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.581230

    authors: Taupin P

    更新日期:2011-08-01 00:00:00

  • Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications.

    abstract:IMPORTANCE OF THE FIELD:Nonsteroidal estrogens have been known since the 1930s. However, the relatively recent (1996) discovery of estrogen receptor subtype beta (ERbeta) suggested a possible paradigm shift away from SERM-like selectivity. Selective ERbeta agonism would potentially allow expansion of estrogenic targeti...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543771003657164

    authors: Mohler ML,Narayanan R,Coss CC,Hu K,He Y,Wu Z,Hong SS,Hwang DJ,Miller DD,Dalton JT

    更新日期:2010-04-01 00:00:00

  • An update on liposomes in drug delivery: a patent review (2014-2018).

    abstract::Introduction: Pharmacotherapy is limited by the inefficient drug targeting of non-healthy cells/tissues. In this pharmacological landscape, liposomes are contributing to the impulse given by Nanotechnology to optimize drug therapy. Areas covered: The analysis of the state-of-the-art in liposomal formulations for drug ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2019.1679767

    authors: El-Hammadi MM,Arias JL

    更新日期:2019-11-01 00:00:00

  • TBK1 inhibitors: a review of patent literature (2011 - 2014).

    abstract:INTRODUCTION:TANK-binding kinase 1 (TBK1) is a noncanonical IκB kinase family member that regulates the innate immune response. Misregulation of TBK1 activity can promote inflammatory disorders and oncogenesis; therefore, TBK1 inhibitors are considered a promising therapy for inflammation and cancer. AREAS COVERED:In ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2015.1081168

    authors: Yu T,Yang Y,Yin DQ,Hong S,Son YJ,Kim JH,Cho JY

    更新日期:2015-01-01 00:00:00

  • Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2012-2015).

    abstract:INTRODUCTION:The activation of leukocytes and the subsequent immune cascade play an essential role in sterile and infectious inflammation. Dysregulation of these immune responses or excess leukocyte activation can induce tissue damage, organ dysfunction and mortality. Formyl peptide receptors (FPRs) are functionally di...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2016.1216546

    authors: Tsai YF,Yang SC,Hwang TL

    更新日期:2016-10-01 00:00:00

  • Growth hormone secretagogue receptor antagonists.

    abstract::The patent claims peptidic/nonpeptidic inhibitors of the ghrelin receptor, the growth hormone secretagogue receptor (GHSR) 1A. Among these compounds, it was disclosed that the addition in some compounds of a GlyMetAla tripeptide at the N-terminus of the ghrelin peptide agonists converts them into ghrelin receptor anta...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2012.684946

    authors: Costantino L

    更新日期:2012-06-01 00:00:00

  • Apigenin and related compounds stimulate adult neurogenesis. Mars, Inc., the Salk Institute for Biological Studies: WO2008147483.

    abstract::The application is in the field of adult neurogenesis and its therapeutic potential. It aims to characterize the activity of apigenin and related compounds on adult neurogenesis in vivo and in vitro. Apigenin and related compounds are derivatives used in food products. They were administered intraperitoneally and oral...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543770902721279

    authors: Taupin P

    更新日期:2009-04-01 00:00:00

  • Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present).

    abstract::Introduction: The greater interest in TAAR1-mediated potential for the treatment of different pathologies, especially those related to CNS disorders, has given a considerable boost to the search for developing TAAR1-selective small molecules.Areas covered: During the last decade, the medicinal chemistry efforts have a...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1708900

    authors: Tonelli M,Cichero E

    更新日期:2020-02-01 00:00:00

  • Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).

    abstract:INTRODUCTION:The cyclic nucleotides cAMP and cGMP are ubiquitous intracellular second messengers regulating a large variety of biological processes. The intracellular concentration of these biologically relevant molecules is modulated by the activity of phosphodiesterases (PDEs), a class of enzymes that is grouped in 1...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2016.1203902

    authors: Trabanco AA,Buijnsters P,Rombouts FJ

    更新日期:2016-08-01 00:00:00

  • Sulfonamide inhibitors: a patent review 2013-present.

    abstract:INTRODUCTION:Sulfonamide compounds are significant class of synthetic bacteriostatic antibiotics still which used today for the therapy of bacterial infections and those caused by other microorganisms. They are also known as sulfa drugs and were the main source of therapy against bacterial infections before the introdu...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1487400

    authors: Gulçin İ,Taslimi P

    更新日期:2018-07-01 00:00:00

  • Signal transducer and activator of transcription 3 inhibitors: a patent review.

    abstract:IMPORTANCE OF THE FIELD:Aberrant activation of signal transducer and activator of transcription (Stat) 3, a member of the STAT family of proteins, is prevalent in numerous human cancers and is now widely recognized as a critical molecular abnormality and a master regulator of tumor processes. Thus, the identification o...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.539205

    authors: Page BD,Ball DP,Gunning PT

    更新日期:2011-01-01 00:00:00

  • Orexin research: patent news from 2016.

    abstract:INTRODUCTION:The orexin system consists of two G-protein-coupled receptors, orexin 1 and orexin 2 and two endogenous ligands, orexin A and orexin B . It is evolutionarily highly conserved. It is involved in the promotion of wakefulness as well as in anxiety and addictive disorders. In addition, its activation via the O...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1344221

    authors: Boss C,Roch C

    更新日期:2017-10-01 00:00:00

  • Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

    abstract:INTRODUCTION:Chymase is primarily found in mast cells (MCs), fibroblasts, and vascular endothelial cells. MC chymase is released into the extracellular interstitium in response to inflammatory signals, tissue injury, and cellular stress. Among many functions, chymase is a major extravascular source for angiotensin II (...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1531848

    authors: Ahmad S,Ferrario CM

    更新日期:2018-11-01 00:00:00

  • Natural, synthetic and semisynthetic glycolipid inhibitors of glioma growth.

    abstract::Neurostatin, a natural glycosphingolipid inhibitor of astroblast and astrocytoma division, present in mammalian brain, is the modified ganglioside O-acetylated GD1b. It is cytostatic for rat astroblasts, C6 glioma cells and various human astrocytoma lines grades III and IV, with median inhibitory dose values ranging 1...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.14.4.487

    authors: Nieto-Sampedro M,Doncel-Pérez E,Fernández-Mayoralas A

    更新日期:2004-04-01 00:00:00

  • Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014).

    abstract:INTRODUCTION:Melatonin is a neurohormone involved in the regulation of circadian rhythms, with potent antioxidant activity. It has a wide functional repertoire, with effects almost on all tissues and organs. It is mainly used as a dietary supplement for sleep regulation and re-synchronization of disrupted circadian rhy...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.1001739

    authors: Rivara S,Pala D,Bedini A,Spadoni G

    更新日期:2015-04-01 00:00:00